United States securities and exchange commission logo





                             November 10, 2021

       Atabak Mokari
       Chief Financial Officer
       Corcept Therapeutics Inc.
       149 Commonwealth Drive
       Menlo Park , CA 94025

                                                        Re: Corcept
Therapeutics Inc.
                                                            Form 10-K for the
Fiscal Year Ended December 31, 2020
                                                            Filed February 23,
2021
                                                            File No. 000-50679

       Dear Mr. Mokari:

               We have limited our review of your filing to the financial
statements and related
       disclosures and have the following comment. In our comment, we may ask
you to provide us
       with information so we may better understand your disclosure.

              Please respond to the comment within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comment applies to your facts and circumstances, please tell us why in
your response.

                                                        After reviewing your
response to the comment, we may have additional comments.

       Form 10-K for the Fiscal Year Ended December 31, 2020

       Item 9A. Controls and Procedures
       (b) Management's Report on Internal Control Over Financial Reporting,
page 41

   1.                                                   We note your
disclosures in management's report on internal control over financial
                                                        reporting refer to
disclosure controls and procedures. Please amend the filing to provide a
                                                        revised management's
report on internal control over financial reporting to properly
                                                        include a statement
identifying the framework used by management in such evaluation, as
                                                        well as management's
assessment conclusion, in accordance with Item 308(a) of
                                                        Regulation S-K. You may
file an abbreviated amendment that is limited to the cover
                                                        page, an explanatory
note, the complete text of Item 9A, a signature page, and the required
                                                        officer certifications.
 Atabak Mokari
FirstName LastNameAtabak
Corcept Therapeutics Inc. Mokari
Comapany 10,
November  NameCorcept
              2021       Therapeutics Inc.
November
Page 2    10, 2021 Page 2
FirstName LastName
       In closing, we remind you that the company and its management are
responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
absence of action by the staff.

       You may contact Li Xiao at (202) 551-4391 or Angela Connell at (202)
551-3426 with
any questions.



                                                          Sincerely,

                                                          Division of
Corporation Finance
                                                          Office of Life
Sciences